Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Exchange Rate Effect: 2014-2019

Historic Exchange Rate Effect for Coherus Oncology (CHRS) over the last 6 years, with Dec 2019 value amounting to -$106,000.

  • Coherus Oncology's Exchange Rate Effect fell 176.81% to -$106,000 in Q4 2019 from the same period last year, while for Dec 2019 it was -$276,000, marking a year-over-year decrease of 158.97%. This contributed to the annual value of -$276,000 for FY2019, which is 158.97% down from last year.
  • According to the latest figures from Q4 2019, Coherus Oncology's Exchange Rate Effect is -$106,000, which was down 279.66% from $59,000 recorded in Q3 2019.
  • Over the past 5 years, Coherus Oncology's Exchange Rate Effect peaked at $226,000 during Q2 2018, and registered a low of -$271,000 during Q4 2016.
  • For the 3-year period, Coherus Oncology's Exchange Rate Effect averaged around $6,000, with its median value being -$10,000 (2017).
  • Per our database at Business Quant, Coherus Oncology's Exchange Rate Effect spiked by 2,071.43% in 2018 and then crashed by 946.15% in 2019.
  • Coherus Oncology's Exchange Rate Effect (Quarterly) stood at $82,000 in 2015, then tumbled by 430.49% to -$271,000 in 2016, then spiked by 97.42% to -$7,000 in 2017, then surged by 2,071.43% to $138,000 in 2018, then plummeted by 176.81% to -$106,000 in 2019.
  • Its last three reported values are -$106,000 in Q4 2019, $59,000 for Q3 2019, and -$93,000 during Q2 2019.